Foundayo (orforglipron): the daily GLP-1 pill, explained

Foundayo is the first GLP-1 weight-loss pill that isn't a peptide. That one fact explains most of what's different about it: no fasting rule, a daily tablet instead of a weekly shot, and a separate trial record from the semaglutide and tirzepatide drugs you've heard of. FDA cleared it 50 days after Lilly filed, the first new molecule approved under the agency's national priority voucher program ^[2]. If you're comparing it with the injections, the Foundayo vs Zepbound comparison lines the two up side by side.

Foundayo is orforglipron, a new kind of GLP-1 drug

Orforglipron does the same basic job as other GLP-1 drugs. It switches on the GLP-1 receptor, the target of a gut hormone that helps set appetite. The label puts it plainly: "GLP-1 receptors are present in brain regions that regulate appetite" ^[1].

What it does in the body follows from that. Per the label, Foundayo "decreases food intake" and "delays gastric emptying," meaning food leaves the stomach more slowly. That slowing is largest after the first dose and fades over time. The label also says the weight lost was more fat mass than lean mass ^[1].

The new part is the molecule's build. Semaglutide and tirzepatide are peptides, chains of amino acids that stomach acid breaks down easily. That's why semaglutide pills need an absorption helper and strict fasting conditions. Orforglipron is a small molecule, closer in build to a typical tablet medicine, so it survives the gut without those conditions.

Is Foundayo semaglutide or tirzepatide? No

Foundayo is neither. It contains orforglipron and nothing else. Here's how it differs from the two drugs people most often mix it up with:

• Not semaglutide. Semaglutide is the peptide in Ozempic, Wegovy and the semaglutide pills, made by Novo Nordisk. See the semaglutide guide.
• Not tirzepatide. Tirzepatide is the peptide in Zepbound and Mounjaro. It acts on two receptors, GIP and GLP-1; Foundayo acts on GLP-1 only. See the tirzepatide guide.
• Same maker as tirzepatide. Lilly makes both Foundayo and Zepbound, which may be where the mix-up starts. Same company, different drug.

Because they're different molecules, their trial results don't carry over. Zepbound's weight-loss numbers come from tirzepatide trials. Foundayo's come from orforglipron trials, run separately and in different groups of people.

Foundayo is approved for weight management only

The label covers one use: reducing excess body weight and keeping it off long term, alongside a reduced-calorie diet and more physical activity. It applies to adults with obesity, or adults with overweight plus at least one weight-related condition ^[1]. It isn't approved for children or teens.

Foundayo isn't approved to treat type 2 diabetes. Lilly has said it filed for that use, but that's a company statement, and FDA hasn't approved it as of this update ^[3]. The diabetes trials below show what orforglipron did in that group. They don't make it a diabetes drug.

In trials, the top dose averaged about 11% weight loss

ATTAIN-1 is the main weight-loss trial. It randomized 3,127 adults with obesity and no diabetes to one of three daily doses or placebo for 72 weeks. Average weight loss was 7.5%, 8.4% and 11.2% by dose, against 2.1% on placebo. At the top dose, 54.6% of people lost at least 10% of their weight and 36.0% lost at least 15% ^[7]. Eli Lilly funded the trial.

ATTAIN-MAINTAIN asked a practical question: can a pill hold onto weight lost on an injection? People who had already lost weight on tirzepatide or semaglutide switched to orforglipron or placebo. A year later, the orforglipron groups had kept most of their earlier loss, while the placebo groups regained more ^[8]. The authors note the trial had no group that stayed on the injection, so it can't say whether the pill holds weight as well as continuing the shot.

The label says once a day, with or without food

This is the practical difference most readers notice. The label says to take Foundayo "orally once daily, with or without food," to swallow tablets whole, and not to take more than one tablet a day ^[1]. There's no empty-stomach window and no limit on water.

Dosing starts low and rises over months. The label starts at 0.8 mg once daily and allows up to 17.2 mg once daily. Your prescriber sets the pace in between, based on how you respond and what you tolerate. Some other medicines change the right dose, which is one more reason the schedule belongs with your prescriber and the label, not a chart online.

Side effects are mostly digestive, with the usual GLP-1 warnings

The most common side effects on the label, reported by at least 5% of people, are nausea, constipation, diarrhea, vomiting, indigestion, abdominal pain, headache, bloating, fatigue, burping, acid reflux, gas and hair loss ^[1]. In ATTAIN-1, side effects led 5.3% to 10.3% of people on orforglipron to stop, compared with 2.7% on placebo ^[7].

• Boxed warning. Like the other GLP-1 drugs, Foundayo carries a warning about thyroid C-cell tumors seen in rodents. It isn't for people with a personal or family history of medullary thyroid cancer or MEN 2 ^[1].
• Other label warnings. Pancreatitis, severe digestive reactions, kidney injury from dehydration, low blood sugar, allergic reactions, gallbladder disease, diabetic eye complications in type 2 diabetes, and aspiration risk under anesthesia.
• Drug interactions. Foundayo is broken down by an enzyme called CYP3A4. The label says to avoid strong CYP3A4 inducers and not to exceed simvastatin 20 mg a day alongside it ^[1]. Bring your full medication list to your prescriber.
• Birth-control pills. Because Foundayo slows the stomach, the label advises people on oral hormonal contraceptives to switch methods or add a barrier method for 30 days after starting and after each dose increase ^[1].

For a fuller picture of what GLP-1 side effects look like week to week, the tirzepatide side effects guide covers the same class of digestive effects in more depth.

Foundayo vs the Wegovy pill: different molecules, different rules

Both are daily weight-loss pills, so this is the comparison many readers actually face. They aren't versions of each other. The Wegovy pill is semaglutide from Novo Nordisk; Foundayo is orforglipron from Lilly. The biggest day-to-day difference is the food rule, and the biggest label difference is heart protection.

The two weight results come from different trials with different people, lengths and doses, so they can't be ranked against each other. No trial has put the two pills head to head for weight loss. The one direct comparison, ACHIEVE-3, was in type 2 diabetes against the diabetes doses of oral semaglutide, and it measured blood sugar. Orforglipron lowered A1C more there, though more people stopped orforglipron because of side effects (9% to 10%, against 4% to 5%) ^[10].

If a daily pill is what you want, the deciding questions are practical. Can you keep a fasting routine every morning? Do you have heart disease, where the Wegovy pill carries a labeled benefit? The semaglutide pill guide covers the Wegovy pill in full, and the Wegovy pill vs injection comparison explains how it stacks up against the weekly shot.

Foundayo vs Zepbound: a pill trades some weight loss for convenience

Zepbound is a weekly tirzepatide injection from the same company. In its main trial, the top dose averaged 20.9% weight loss at 72 weeks ^[13], higher than the 11.2% Foundayo's top dose reached over the same length ^[7]. Those were separate trials, and no head-to-head obesity trial exists. Zepbound also carries a sleep apnea approval that Foundayo doesn't. Foundayo's case is a daily tablet with no injection and no food rule. The full Foundayo vs Zepbound comparison covers results, side effects and cost, and the Zepbound guide covers the shot on its own.

Self-pay runs $149 to $299 a month on LillyDirect

Lilly sells Foundayo directly to people paying cash through LillyDirect. The price depends on the dose, and two of the lower doses are on a temporary discount through the end of 2026 ^[4].

So the price climbs as your dose climbs, then flattens at $299 from 9 mg up. If you get Foundayo through a telehealth service, the medication price is usually the same maker price plus that service's own membership or visit fee. The providers listed on this page show what each one charges. To work out a monthly total for any plan, try the monthly cost calculator.

You need a prescription, from your own doctor or a telehealth service

Foundayo is prescription-only. You can get it from your own doctor, who sends the prescription to a pharmacy or to LillyDirect. Or you can use a telehealth service, where a licensed clinician reviews your health history online. Because it's a pill with no food rule, it fits programs built around oral options. The GLP-1 pill programs board scores the services that prescribe it.

Before you start, ask your prescriber three things: whether any of your current medicines interact with it, what your birth-control plan should be in the first months, and how your dose will be adjusted. If you're weighing it against a weekly shot, the Wegovy guide and the Zepbound guide cover those options.